Is the US looking for alternatives to LASIK?

Article

Sales of the Visian ICL (Implantable Collamer Lens; STAAR Surgical Company) grew 38% in the US over the previous year, while the rate of LASIK procedures declined by approximately 40% in the second quarter of last year.

Sales of the Visian ICL (Implantable Collamer Lens; STAAR Surgical Company) grew 38% in the US over the previous year, while the rate of LASIK procedures declined by approximately 40% in the second quarter of last year.

The fall in the number of laser-based refractive procedures coincides with the investigation by the US Food and Drug Administration Ophthalmic Device panel into patient satisfaction and quality of life post-LASIK, widely (but falsely) reported by the media to be an investigation into the safety of LASIK procedures.

The Visian ICL's benefits over LASIK include its smaller required incision size, which reduces both ocular trauma and recovery time; additionally, although designed to be a permanent implant, the Visian ICL can be removed or replaced if necessary, unlike the irreversible LASIK procedure. In an FDA study, patients implanted with the Visian ICL reported satisfaction rates of >99% at five years.

STAAR Surgical's newly enhanced consumer website, www.visianinfo.com, launched officially on Monday July 14.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.